BriaCell Therapeutics (NASDAQ:BCTX) Trading 4% Higher – Here’s What Happened

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares rose 4% during mid-day trading on Wednesday . The stock traded as high as $3.69 and last traded at $3.61. Approximately 24,906 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 193,781 shares. The stock had previously closed at $3.47.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price target on shares of BriaCell Therapeutics from $15.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, February 3rd.

BriaCell Therapeutics Stock Performance

The company has a market cap of $14.61 million, a PE ratio of -0.30 and a beta of 1.71. The business’s 50-day moving average is $4.15 and its 200 day moving average is $8.48.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings data on Monday, March 17th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($1.94) by ($0.39). Equities research analysts anticipate that BriaCell Therapeutics Corp. will post -2.45 EPS for the current fiscal year.

Institutional Trading of BriaCell Therapeutics

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of BriaCell Therapeutics in the fourth quarter worth about $27,000. Cantor Fitzgerald L. P. purchased a new position in shares of BriaCell Therapeutics during the fourth quarter valued at approximately $32,000. Finally, Vontobel Holding Ltd. raised its holdings in shares of BriaCell Therapeutics by 37.5% during the fourth quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock valued at $62,000 after acquiring an additional 30,000 shares in the last quarter. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.